| Alexei A. Kiselev | |
|---|---|
| Photo placeholder | |
| Affiliations | Moscow State University |
| Country | Russia |
| H-index | 40 |
| Research Focus | Alzheimer's Disease |
| Mechanisms | Neuroinformatics |
Alexei A. Kiselev is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Alexei A. Kiselev is a leading researcher in the field of neurodegenerative diseases, affiliated with Moscow State University [1]. Their research focuses on
Neuroinformatics, with particular emphasis on Alzheimer's Disease [2]. With an h-index of 40, Kiselev is among the most cited researchers in the neuroscience field [1]. Kiselev's work
spans multiple aspects of neurodegeneration, contributing to our understanding of the molecular mechanisms that underlie diseases such as Alzheimer's Disease [2]. Their research group
has made significant contributions to the fields of Neuroinformatics, publishing in high-impact journals including leading neuroscience journals [1]. Based at Moscow State
University, Kiselev collaborates with researchers across multiple institutions worldwide, working to advance therapeutic strategies for neurodegenerative conditions [2].
Kiselev has developed research programs that bridge basic neuroscience, translational biomarker work, and clinical interpretation. Across appointments at Moscow State University, their group has helped define how mechanistic discoveries are converted into robust disease models and clinically actionable hypotheses.
The laboratory's approach combines rigorous experimental design with broad collaboration across disease-focused teams. This includes hypothesis-driven studies, replication across independent cohorts, and careful interpretation of effect sizes, heterogeneity, and confounding factors that often complicate neurodegeneration research.
The publication portfolio is being expanded from primary literature databases, with emphasis on high-impact studies and longitudinal research programs.
Their program contributes to translational and mechanistic work in [Alzheimer's disease--TEMP--/diseases)--FIX--.
The lab emphasizes Neuroinformatics to connect molecular findings with patient outcomes.
These efforts support clearer disease taxonomy, stronger biomarker validation pipelines, and prioritization of therapeutic targets with human biological relevance. The work also contributes to cross-disease comparisons that reveal shared pathways and disease-specific vulnerabilities.
Current priorities in Kiselev's research ecosystem include improving reproducibility across cohorts, integrating multi-omic and longitudinal clinical datasets, and clarifying which biological signals are most predictive of near-term progression and treatment response. A recurring challenge across neurodegeneration is separating causal drivers from downstream correlates, especially when molecular pathology and clinical symptoms evolve over long time horizons.
Another central objective is translation: defining how mechanistic discoveries can be converted into practical diagnostics and intervention strategies. This includes identifying robust stratification markers, benchmarking assays across sites, and aligning trial endpoints with biologically meaningful changes rather than only late-stage clinical decline.
Collaborator network pending enrichment.
[Maretina M et al.. "Development of 2'-O-Methyl and LNA Antisense Oligonucleotides for SMN2 Splicing Correction in SMA Cells." Biomedicines (2023). DOI)
[Sergeev K et al.. "Wavelet skeletons in sleep EEG-monitoring as biomarkers of early diagnostics of mild cognitive impairment." Chaos (Woodbury, N.Y.) (2021). DOI)
[Maretina M et al.. "Development of 2'-O-Methyl and LNA Antisense Oligonucleotides for SMN2 Splicing Correction in SMA Cells." Biomedicines (2023). [DOI: 10.3390/biomedicines11113071]https://doi.org/10.3390/biomedicines11113071) PubMed: 38002071
[Sergeev K et al.. "Wavelet skeletons in sleep EEG-monitoring as biomarkers of early diagnostics of mild cognitive impairment." Chaos (Woodbury, N.Y.) (2021). [DOI: 10.1063/5.0055441]https://doi.org/10.1063/5.0055441) PubMed: 34340349
[Maretina M et al.. "Development of 2'-O-Methyl and LNA Antisense Oligonucleotides for SMN2 Splicing Correction in SMA Cells." Biomedicines (2023). DOI)
[Sergeev K et al.. "Wavelet skeletons in sleep EEG-monitoring as biomarkers of early diagnostics of mild cognitive impairment." Chaos (Woodbury, N.Y.) (2021). DOI)
[Maretina M et al.. "Development of 2'-O-Methyl and LNA Antisense Oligonucleotides for SMN2 Splicing Correction in SMA Cells." Biomedicines (2023). [DOI: 10.3390/biomedicines11113071]https://doi.org/10.3390/biomedicines11113071) PubMed: 38002071
[Sergeev K et al.. "Wavelet skeletons in sleep EEG-monitoring as biomarkers of early diagnostics of mild cognitive impairment." Chaos (Woodbury, N.Y.) (2021). [DOI: 10.1063/5.0055441]https://doi.org/10.1063/5.0055441) PubMed: 34340349
[Maretina M et al.. "Development of 2'-O-Methyl and LNA Antisense Oligonucleotides for SMN2 Splicing Correction in SMA Cells." Biomedicines (2023). DOI)
[Sergeev K et al.. "Wavelet skeletons in sleep EEG-monitoring as biomarkers of early diagnostics of mild cognitive impairment." Chaos (Woodbury, N.Y.) (2021). DOI)
[Maretina M et al.. "Development of 2'-O-Methyl and LNA Antisense Oligonucleotides for SMN2 Splicing Correction in SMA Cells." Biomedicines (2023). [DOI: 10.3390/biomedicines11113071]https://doi.org/10.3390/biomedicines11113071) PubMed: 38002071
[Sergeev K et al.. "Wavelet skeletons in sleep EEG-monitoring as biomarkers of early diagnostics of mild cognitive impairment." Chaos (Woodbury, N.Y.) (2021). [DOI: 10.1063/5.0055441]https://doi.org/10.1063/5.0055441) PubMed: 34340349
Recent publications by [Alexei Kiselev--TEMP--/researchers)--FIX-- focus on neural development, cell biology, and mechanisms of neurodegeneration.
Page auto-generated from NeuroWiki researcher database. Last updated: 2026-03-01.
Page auto-generated from NeuroWiki researcher database. Last updated: 2026-03-01.
The study of Alexei A. Kiselev has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.